CLINICAL STUDIES ON TMS-19-Q IN THE FIELD OF OTORHINOLARYNGOLOGY

• Published in: CHEMOTHERAPY Vol. 32; no. Supplement6; pp. 436 - 451
• Main Authors: ZUSHO, HIROYUKI, YAMAMOTO, KENSHI, KOBAYASHI, HITOME, SHIRAKURA, MASATO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1984
• DOI: 10.11250/chemotherapy1953.32.Supplement6_436
• EISSN: 1884-5894
• ISSN: 0009-3165

The clinical effects of a new macrolide antibiotic, TMS-19-Q, were examined and the following results were obtained. 1) Clinical effects: TMS-19-Q·GC tablet, 600 mg/day, was orally administered to 57 cases of infections in otorhinolaryngological field, and the clinical effects were examined in 55 cases except for 2 cases. The results obtained were excellent in 21 cases, good in 21 cases, fair in 5 cases and poor in 8 cases, and an efficacy rate was 76.4%. Six of 8 non-effective cases were acute exacerbation of chronic otitis media, from 5 cases of whom Pseudomonas and Proteus were detected to which this drug has no activity. 2) Bacteriological effects: GNB was detected in many of the clinical isolates from otitis media, whereas GPC was frequently isolated from other diseases. The disapperance rate in all the strains of GPC was as high as 80%. The peak level of MIC of TMS-19-Q against both S. aureus and Streptococcus was 0.39 μg/ml, i.e., the antibacterial activities of this drug were superior to JM and MDM and slightly inferior to EM. It was found that TMS-19-Q had a interesting characteristic of the lowest resistant rate. In particular, TMS-19-Q showed the excellent antibacterial activities against S. pyogenes and S. pneumoniaewhich are EM-resistant bacteria and against which an increase in macrolide resistant bacteria has been indicated. 3) Side effects. As with side effects, nausea and vomiting were observed in 1 case but these symptoms were disappeared without interruption of medication and the causal relationship to this drug was unknown. Laboratory examination revealed no abnormal findings except for slight increase in S-GOT, S-GPT, BUN and eosinocytes which were found in each one case. From the results of the present study, TMS-19-Q seemed to be useful for treatment of mild or moderate infections in otorhinolaryngological field.